Stephen Brozak
Stock Analyst at WBB Securities
(3.81)
# 1,898
Out of 4,442 analysts
80
Total ratings
43.4%
Success rate
10.3%
Average return
Main Sectors:
Stocks Rated by Stephen Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $17.26 | +120.16% | 16 | Mar 26, 2026 | |
| OMER Omeros | Maintained: Buy | $45 → $55 | $10.48 | +424.81% | 12 | Jan 8, 2026 | |
| CELU Celularity | Upgraded: Buy | $6 | $0.6998 | +757.39% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterated: Buy | $13 | $1.37 | n/a | 6 | Mar 31, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Upgraded: Buy | $31 → $25 | $7.08 | n/a | 9 | Jun 30, 2024 | |
| CFRXQ ContraFect Corporation | Upgraded: Buy | $6.5 → $560 | $0.000001 | n/a | 3 | Jun 8, 2022 | |
| RDHL RedHill Biopharma | Maintained: Buy | $20 → $16 | $0.926 | n/a | 5 | May 28, 2021 | |
| LSTA Lisata Therapeutics | Initiated Coverage: Buy | $70 → $6.8 | $3.47 | n/a | 3 | May 14, 2019 | |
| SCYX SCYNEXIS | Reiterated: Buy | $8 | $3.82 | n/a | 6 | Apr 18, 2019 | |
| ADMA ADMA Biologics | Upgraded: Buy | $9 → $12 | $8.69 | n/a | 2 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $20 | $0.0004 | n/a | 6 | Mar 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.0001 | n/a | 5 | Oct 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $10 | $32.98 | n/a | 2 | Dec 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $13 | $0.429 | n/a | 1 | Oct 29, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $78.68 | n/a | 1 | May 10, 2011 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.08 | n/a | 1 | Jan 8, 2010 |
Sarepta Therapeutics
Mar 26, 2026
Maintained: Buy
Price Target: $38
Current: $17.26
Upside: +120.16%
Omeros
Jan 8, 2026
Maintained: Buy
Price Target: $45 → $55
Current: $10.48
Upside: +424.81%
Celularity
Sep 9, 2025
Upgraded: Buy
Price Target: $6
Current: $0.6998
Upside: +757.39%
Marker Therapeutics
Mar 31, 2025
Reiterated: Buy
Price Target: $13
Current: $1.37
Upside: n/a
Arcturus Therapeutics Holdings
Jun 30, 2024
Upgraded: Buy
Price Target: $31 → $25
Current: $7.08
Upside: n/a
ContraFect Corporation
Jun 8, 2022
Upgraded: Buy
Price Target: $6.5 → $560
Current: $0.000001
Upside: n/a
RedHill Biopharma
May 28, 2021
Maintained: Buy
Price Target: $20 → $16
Current: $0.926
Upside: n/a
Lisata Therapeutics
May 14, 2019
Initiated Coverage: Buy
Price Target: $70 → $6.8
Current: $3.47
Upside: n/a
SCYNEXIS
Apr 18, 2019
Reiterated: Buy
Price Target: $8
Current: $3.82
Upside: n/a
ADMA Biologics
Apr 4, 2019
Upgraded: Buy
Price Target: $9 → $12
Current: $8.69
Upside: n/a
Mar 8, 2019
Reiterated: Buy
Price Target: $12 → $20
Current: $0.0004
Upside: n/a
Oct 4, 2018
Reiterated: Buy
Price Target: $9
Current: $0.0001
Upside: n/a
Dec 6, 2017
Reiterated: Buy
Price Target: $40 → $10
Current: $32.98
Upside: n/a
Oct 29, 2015
Upgraded: Buy
Price Target: $13
Current: $0.429
Upside: n/a
May 10, 2011
Rated: Buy
Price Target: n/a
Current: $78.68
Upside: n/a
Jan 8, 2010
Maintained: Buy
Price Target: n/a
Current: $4.08
Upside: n/a